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Background.A l l - trans-retinoic acid (atRA) is eﬀective for many proliferative diseases. We investigated the protective eﬀects of atRA
against atherosclerosis. Methods. Rabbits were randomly allocated to receive basal diet or an HFD for 4 weeks. HFD group then
received rosuvastatin (3mg/day), atRA (5mg/kg/day), or the same volume of vehicle, respectively, for next 8 weeks. Results. HFD
group showed increases in plasma lipids and aortic plaque formation. P-selectin expression and ﬁbrinogen binding on platelets or
deposition on the intima of the aorta also increased signiﬁcantly as did the levels of TNF-α,I L - 6 ,a n dﬁ b r i n o g e ni np l a s m a .A f t e r
8 weeks of treatment with atRA, there was a signiﬁcant decrease in plasma lipids and improvement in aortic lesions. AtRA also
inhibited the expression of P-selectin and ﬁbrinogen binding on platelets and deposition on the intima of the aorta. Conclusion.
AtRA can ameliorate HFD-induced AS in rabbits by inhibiting platelet activation and inﬂammation.
1.Introduction
All-trans-retinoic acid (atRA) is a family of signalling mole-
cules that are chemically related to vitamin A (retinol). AtRA
has potent in vitro eﬀects on a number of processes involved
in vascular injury and repair, such as modulating smooth
muscle cell (SMC) proliferation and inducing SMC diﬀeren-
tiation [1–4]. Recently, atRA was shown to limit restenosis
after balloon angioplasty in a rabbit model [5], as well as
favourable eﬀects in reducing neointimal mass and eliciting
geometric remodelling in injured rat carotid artery [6].
However, to date there are no reports concerning its role in
high-fat diet- (HFD-) induced atherosclerosis (AS).
ASisawidespreadandoneofthemostdangerouscardio-
vascular diseases which cause considerable threat to human
health worldwide. The formation and development of AS is
al o n g - t e r mp r o c e s s[ 7–9] which usually lasts for decades
and results from complicated environmental factors. The
accumulationoflow-densitylipoproteins(LDLs)inthewalls
of arteries is thought to be an initiator of AS, which in
turn induces the migration of mononuclear cells and devel-
opment of inﬂammation [7]. Eventually, the extracellular
matrix interacts with migrating cells to form plaques, which
constrict the arteries making them less ﬂexible and more
likely to impede blood ﬂow [10, 11]. Recently, the activation
of platelets and P-selectin are thought to play a central role
in homeostasis and thrombosis, which also contribute to the
formationofAS,astheyhavebeenshowntoactivelypromote
atherosclerotic lesion development [12, 13]. It has been
shown that P-selectin is expressed in mononuclear phago-
cytes, endothelial cells, and SMCs from atheroma [11, 12].
Intracellular P-selectin also has the potential to translocate
rapidly to the cell surface following stimulation by adenosine
diphosphate (ADP), thrombin, collagen, and other inﬂam-
matory stimuli [14, 15]. On the other hand, ﬁbrinogen
has been implicated in the development of inﬂammation,
thrombosis, and AS and has been shown to promote P-
selectin expression on the surface of platelets [16, 17].
The present study was undertaken to investigate the pos-
sible therapeutic eﬀects of atRA on HFD-induced AS, with2 Journal of Biomedicine and Biotechnology
a special focus on its potential to inhibit platelet activation,
prevent inﬂammation, and lower blood lipids and reduce
aortic lesions, while rosuvastatin was used as a positive con-
trol.
2. Methods
2.1. Animal Procedures. New Zealand male rabbits (ordinary
class)werepurchasedfromanexperimentalanimalfacilityin
Nanjing,China.Therabbits(2.0±0.2kg)weremaintainedin
individual cages under moderate temperature and changing
light (12-hour light, 12-hour dark) conditions with access to
food and clean water. After a 3-day acclimation period, the
rabbits were randomly divided into two groups. The control
group (n = 6) was given a basal diet, while another group
wasgivenHFDcomprising5%lardand1%cholesterol.Four
weeks later, animals in HFD group were divided into three
groups, and received either rosuvastatin calcium (3mg/day),
atRA (5mg/kg/day), or the same volume of vehicle by intra-
gastric administration for 8 weeks (n = 6/group). Rosuvas-
tatin and atRA were dissolved with water.
At the end of the experiment, the rabbits were fasted
for 8 hours prior to anaesthesia (3% pentobarbital w/v
administered at 1mL/kg). Blood was collected from the
common carotid artery. The rabbits were sacriﬁced, and the
aortas were carefully removed and cut open. The tissue was
observed and then placed in 10% (w/v) neutral formalin for
24 hours. Animal experimental procedures were conducted
in accordance with the Internal Animal Care and Use
Committee of the Anhui Medical University and complied
with the Guide for the Care and Use of Laboratory.
2.2. Reagents. Rosuvastatin calcium was purchased from
AstraZeneca; atRA and ADP were purchased from Sigma.
Thrombin was purchased from Pharmaceutical Co., Ltd.,
Hunan. Anti-rabbit CD62-P FITC-conjugated antibody was
purchased from Bioss, Beijing. Chicken polyclonal anti-
Fibrinogen(FITC)antibodywaspurchasedfromAbcam.SP-
9000/9001/9002 Histostain-Plus Kits were purchased from
ZYMED.
2.3. The Blood Collection and the Platelet Preparation. Blood
samples were collected in tubes containing 3.8% sodium
citrate (1/9 v/v) for biochemical measurements and ﬂow
cytometry. Blood sample was centrifuged at 1000g for 10
minutestocollecttheplasma.Platelet-richplasma(PRP)was
obtained by centrifugation at 300g for 10 minutes. Platelets
were then isolated from the PRP using PBS to wash twice as
previously described [13, 17].
2.4. Detection of the Platelet P-Selectin (CD62-P) Expression
and the Fibrinogen Binding by Flow Cytometry. Resting
platelets and platelets activated by thrombin (1U/mL) or
ADP (ﬁnal concentration is 20uM) were incubated with
FITC-conjugated anti-rabbit CD62P or ﬁbrinogen for 30
minutes at room temperature in the dark. PBS (0.5mL)
was added to the sample immediately before acquisition of
data. All samples were analyzed by ﬂow cytometry by FC500
(Beckman Coulter), using 10,000 events per sample with
light scatter and ﬂuorescence channels set at a logarithmic
gain. The platelet population was analyzed for mean ﬂuores-
cence intensity (MFI).
2.5. Biochemical Measurement. The concentrations of plas-
ma lipids were determined using diagnostic enzyme assay
kits. Plasma ﬁbrinogen, IL-6, and TNF-α were measured
using a Quantikine rabbit ﬁbrinogen, IL-6, and TNF-α
enzyme-linked immunosorbent assay (ELISA) kit (R&D Sys-
tems).
2.6. Morphology and Immunohistochemistry. The root of the
aorta from sacriﬁced animals was longitudinally cut and
ﬁxed in 4% paraformaldehyde overnight. Then, the tis-
sue specimens were cut at 5μm thickness for subsequent
hematoxylin-eosin (HE) staining or immunohistochemistry
analysis. The method for HE staining of aortic tissues
was conducted according to the previous report [18].
Immunohistochemistry analysis was performed according
to the method [19]. Brieﬂy, sections of aortic tissues were
deparaﬃnised, rehydrated, and ﬁxed with methanol-0.3%
H2O2 solution for 30min at room temperature. The antigen
was prepared by quick cooling 3min after highly compressed
heating.TheprimaryantibodyagainstCD62-Porﬁbrinogen
was added and incubated overnight. Then, the sections of
aortic tissues were incubated with biotinylated antibody
(anti-rat IgG) and horseradish streptavidin for 30min at
37◦C, respectively. Finally, the samples were incubated with
diaminobenzidine (DAB) for coloration and counterstained
with hematoxylin for 2min to stain the nuclei bluish. The
positively stained cells showed brown color; photographs
were taken using the Image-Pro Plus 5.1 image operation
system. The aortic intima-media thickness and vascular
wall thickness were measured by JD-801 pathological image
analysis system with total 3 slices, each slice was randomly
selected ﬁve view, and then took a mean value (μm).
2.7. Statistical Analysis. All the statistical analyses were un-
dertakenusingtheSPSSprogram,version13.0,forWindows.
All data are expressed as mean ± standard deviation (SD).
Comparisons between groups were carried out using one-
way analysis of variance (ANOVA) and Student-Newman-
Keuls (SNK) method. Values of P<0.05 were regarded as
statistically signiﬁcant.
3. Results
3.1. atRA Improved Plasma Lipids in HFD-Induced AS Rab-
bits. Compared with control group, HFD-induced signif-
icant increases in plasma lipids, including total choles-
terol(Total-C),low-densitylipoproteincholesterol(LDL-C),
high-density lipoprotein cholesterol (HDL-C), and triglyc-
erides (TG). Oral administration of rosuvastatin or atRA
both signiﬁcantly reduced Total-C and LDL-C, and both
signiﬁcantly increased HDL-C under HFD feeding (Table 1).
These ﬁndings suggest that atRA intervention may help to
restore the lipid imbalance induced by HFD.
3.2. atRA Ameliorated Arterial Plaques in HFD-Induced AS
Rabbits. ThecharacteristicsofarteriallesionswereexaminedJournal of Biomedicine and Biotechnology 3
Table 1: Levels of plasma lipids in diﬀerent groups (mmol/L).
Group Total-C LDL-C HDL-C TG
Control 1.51 ±0.56 0.70 ±0.33 0.66 ±0.36 0.23 ±0.11
HFD 29.37 ±4.36∗ 24.57 ±4.57∗ 2.05 ±1.39∗ 2.72 ±2.42∗
Rosuvastatin 16.27 ±2.40 9.21 ±1.27 5.75 ±2.32 1.39 ±0.98
atRA 17.24 ±4.44 12.92 ±3.19 3.35 ±1.55 0.90 ±0.78
∗P<0.05 compared to control group; P<0.05 compared to HFD group.
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Figure 1: Characteristics of arterial lesions. Pathological sections of arterial lesions were examined by HE staining in diﬀerent groups. In
the control group (a), the vessel walls were thin and smooth with even thicknesses; in the HFD group (b), there were more foam cells
and necrotic substances in the intima. Compared with the HFD group, there were less foam cells, necrotic substances in the intima from
rosuvastatin group (c) and atRA group (d) (magniﬁcation ×200). Statistical results of aortic intimal thickness (e) and maximal vessel wall
thickness (f) among diﬀerent groups; ∗P<0.05 compared to control group, P<0.05 compared to HFD group.4 Journal of Biomedicine and Biotechnology
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Figure 2: Platelet ﬁbrinogen binding in diﬀerent groups. Platelets isolated from rabbits were incubated with FITC-labelled anti-ﬁbrinogen
antibody and analyzed with ﬂow cytometry to examine the platelets surface change. Representative histograms are shown. (a) The binding
of ﬁbrinogen on the resting platelets surface from diﬀerent groups. (b) The binding of ﬁbrinogen on the thrombin-activated platelets from
diﬀerent groups. (c) The binding of ﬁbrinogen on the ADP-activated platelets from diﬀerent groups. (d) Mean ﬂuorescence intensity (MFI)
of ﬁbrinogen binding on platelets surface in diﬀerent groups. Data are mean ± standard deviation (SD). Comparisons between groups were
carried out using one-way analysis of variance (ANOVA) and Student-Newman-Keuls (SNK) method (n = 6). ∗∗P<0.01 compared to
control group, P<0.05, P<0.01 compared to HFD group.
by pathological section HE staining using light microscopy.
In control group, the vessel walls were round with even
thicknesses. The inner and the outer elastic plates were
clear and complete. The endothelial cell core was stained
and evenly arranged. No SMCs were seen underneath the
endothelium (Figure 1(a)).
In HFD group, the vessel walls were uneven, and signif-
icant hyperplasia of intima was present. There was evidence
of foam cells and necrotic substances, where cholesterol
crystals and a few inﬂammatory cells were observed. The
inner elastic plates were broken, and a large proportion of
SMCs with spindle-shape cores were arranged in disorder
(Figure 1(b)).TreatmentwithrosuvastatinandatRAresulted
in more even blood vessels, smoother intima, fewer foam
cells and inﬂammatory cells, and less necrotic substances
(Figures 1(c) and 1(d)). Moreover, we measured the aortic
intimal thickness and maximal vessel wall thickness in this
study. We observed that HFD feeding resulted in transparent
increases in either aortic intimal thickness and maximal
vessel wall thickness, which were signiﬁcantly decreased in
either atRA or rosuvastatin-treated groups (Figures 1(e)
and 1(f)).
3.3. atRA Inhibited Expression of CD62-P and Fibrinogen
Binding in Platelets. Platelet activation was investigated by
checking platelet CD62-P expression and ﬁbrinogen binding
by ﬂow cytometry. As shown in Figures 2 and 3, the percent-
age and MFI of ﬁbrinogen and CD62-P were signiﬁcantly
lower in resting platelets from all groups compared with
ﬁndings in thrombin and ADP-stimulated platelets. Platelets
from the control group (in either resting or activated states)
had lower ﬁbrinogen and CD62-P expression compared with
that seen in the HFD, rosuvastatin, and atRA groups. How-
ever, when compared to HFD group, platelets from rosuvas-
tatin and atRA groups had signiﬁcantly lower expression of
ﬁbrinogen and CD62-P on platelet surfaces, suggesting that
atRA suppressed platelet activation.
3.4.atRARepressedDepositionofFibrinogenandExpressionof
CD62-P on the Arteries. As shown in Figures 4(a) and 5(a),
respectively, a very low level of ﬁbrinogen deposition and
CD62-P expression was found in the intima from the control
group, in comparison with that in the HFD group (Figures
4(b) and 5(b)). But rosuvastatin or atRA treatment resulted
in improvements in ﬁbrinogen deposition and CD62-PJournal of Biomedicine and Biotechnology 5
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Figure 3: Platelet CD62-P expressions in diﬀerent groups. Isolated platelets were incubated with FITC-labelled anti-CD62P antibody, and
surface CD62-P changes were monitored by ﬂow cytometry. Representative histograms from every group are shown. (a) The expression
of CD62-P on the resting platelets surface from diﬀerent groups. (b) The expression of CD62-P on the thrombin-activated platelets from
diﬀerent groups. (c) The expression of CD62-P on the ADP-activated platelets from diﬀerent groups. (d) Mean ﬂuorescence intensity (MFI)
of CD62-P expression on platelets surface in diﬀerent groups. Data are mean ± standard deviation (SD). Comparisons between groups were
carried out using one-way analysis of variance (ANOVA) and Student-Newman-Keuls (SNK) method (n = 6). ∗∗P<0.01 compared to
control group, P<0.05, P<0.01 compared to HFD group.
Table 2: Levels of ﬁbrinogen and cytokines in diﬀerent groups.
Group Fibrinogen (g/L) TNF-α (pg/mL) IL-6 (pg/mL)
Control 2.42 ±0.29 79.54 ±12.53 38.76 ±6.36
HFD 4.03 ±0.36∗ 142.12 ±14.57∗ 62.04 ±6.39∗
Rosuvastatin 3.69 ±0.24 101.88 ±16.78 49.97 ±7.32
atRA 2.87 ±0.30 95 ±11.89 43.82 ±5.71
∗P<0.05 compared to control group; P<0.05 compared to HFD group.
expression in the intima of arteries (Figures 4(c) and 4(d))
and (Figures 5(c) and 5(d)). Lesions from HFD group con-
tained extensive foam cell accumulation which was not ob-
vious in atRA treatment group. The presence of signiﬁcantly
larger lesions in HFD group than control group suggested
that ﬁbrinogen and CD62-P may play a role in atherosclerot-
ic lesion growth.
3.5. atRA Lowered Levels of Inﬂammatory Cytokines and
Fibrinogen in Plasma. Beside IL-6 and TNF-α, plasma ﬁb-
rinogen is also an important marker of inﬂammation [20].
Levels of ﬁbrinogen, TNF-α, and IL-6 were signiﬁcantly
higher in the HFD group than in the control group (Table 2),
while they were signiﬁcantly lowered by both rosuvastatin
and atRA treatment. Moreover, the eﬀect was numerically
more marked with atRA than with rosuvastatin.
4. Discussion
AtRA is an active metabolite of vitamin A that inhibits cell
migration, regulates extrinsic coagulation, and promotes cell
diﬀerentiation [1–3, 21, 22]. Although earlier studies had
f o c u s e do ni t sa n t i t u m o re ﬀects [21–23], it has been shown
that atRA limits restenosis after balloon angioplasty in a6 Journal of Biomedicine and Biotechnology
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Figure 4: Fibrinogen deposition in arteries from diﬀerent groups with immunohistochemistry. Areas of positive ﬁbrinogen deposition are
shown in brown. The representative photographs of immunohistochemistry from diﬀerent groups are shown. In the control group (a),
the deposition of ﬁbrinogen in the intima was minimum, while in the HFD group (b), there was much more ﬁbrinogen deposition in the
intima. In the rosuvastatin group (c), there was less ﬁbrinogen deposition in the intima compared with HFD group. In the atRA group (d),
the ﬁbrinogen deposition was signiﬁcantly less in comparison with either HFD or rosuvastatin group (magniﬁcation ×400).
rabbit model [5], suggesting its potential role in other AS
models. In current study, we found that oral administra-
tion of atRA improved characteristics of AS and lowered
expressions of P-selectin and ﬁbrinogen and concentrations
of inﬂammatory cytokines in AS rabbits induced by HFD.
Rosuvastatin, a classical lipid-lowering drug of statins in
clinic[10,24],wasusedasapositivecontrol,andcomparable
eﬀectwasfoundbetweenatRA-androsuvastatin-thetreated
rabbits in current study.
The initial stage of AS involves the adherence of mono-
cytes to the surface of the injured endothelium, a process
facilitated by adhesion molecules [7]. Then, activated plate-
lets cause the Weibel-Palade body release leading to CD62-
P mediated leukocyte rolling, suggesting that platelet CD62-
P promotes development of inﬂammation and deterioration
of AS [25–27]. On the other hand, ﬁbrinogen deposition
stimulates chemokine secretion and facilitates a neutrophil-
endothelial interaction in septic shock [16, 28]. We have pre-
viously shown that ﬁbrinogen enhances platelet intracellular
CD62-P levels and aﬀects CD62-P expression on the surface
of platelets [13, 17, 27, 29]. These ﬁndings support a role of
ﬁbrinogen in AS and suggest that CD62-P may contribute to
the formation of AS.
AlthoughbothrosuvastatinandatRAtreatmentsresulted
in eﬀective amelioration of AS in rabbits, much more im-
provement could be found in the atRA group than rosu-
vastatin-treated rabbits, including less aortic plaques, greater
inhibition on ﬁbrinogen deposition, and expression of P-
selectin on platelets and intima of aorta. Moreover, we
found that the lipids-lowering eﬀect between rosuvastatin
and atRA showed a little diﬀerence, For example the extents
of lowering of LDL-C and increasing of HDL-C were greaterJournal of Biomedicine and Biotechnology 7
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Figure 5: CD62-P expressions in atherosclerotic lesion from diﬀerent groups with immunohistochemistry. Representative photographs of
immunohistochemistry from diﬀerent groups are shown. Positive CD62-P expression is shown in brown. In the control group (a), the
expression of CD62-P in the intima was minimum. In the HFD group (b), there was signiﬁcantly increased CD62-P expression in the
intima. In the rosuvastatin group (c), there was less but considerable CD62-P expression in the intima. Compared to the HFD group, there
was signiﬁcantly reduced CD62-P expression in the intima from atRA group (d) (magniﬁcation ×400).
in the rosuvastatin group than atRA. These ﬁndings suggest
that atRA might reduce AS formation through a diﬀerent
mechanism to rosuvastatin. One possibility is that atRA
might inhibit PDGF-induced cell proliferation and induce
apoptosis in aortic SMCs [1–3]. Secondly, a more important
possibility is that atRA might prevent the development of
AS by greater inhibition on the expression of CD62-P and
secretion of ﬁbrinogen, in addition to its lipids-lowering
eﬀect, because P-selectin has been demonstrated to be a
therapeutic target for AS [30].
Clinical and experimental studies support the idea that
chronic inﬂammation plays a major role in the development
of AS [11]. In our study rosuvastatin and atRA were
both shown to counteract the increases in inﬂammatory
cytokinessuchasIL-6andTNF-αresultingfromHFD.These
ﬁndings are in agreement with previous studies [31, 32]
which highlight the role of anti-inﬂammatory properties of
rosuvastatin in preventing the development of AS, includ-
ing inhibition of endothelial cell adhesion and monocyte
adherence, reduction in tissue plasminogen activation, and
suppression of TNF-α and MCP-1 in the vessel wall [33–35].
Fibrinogen is not only implicated in development of cardio-
vascular disease but is also an inﬂammatory marker [20].
The inhibition of ﬁbrinogen and inﬂammatory cytokines
by atRA underscores the anti-inﬂammatory eﬀect by atRA
in AS model [36]. However, it has also been proposed that
atRA may increase foam cell formation and atherosclerotic
lesion via upregulation of CD36 and MCP-1 in vitro [37],
suggesting that the biological functions of atRA in AS are
inclusive which need further investigations.
Taken together, the results of present study warrant the
further investigation of atRA as a potential agent for pre-
venting and treating AS and restenosis. Since the underlying
signal transduction and mechanisms that result in inhibition
of ﬁbrinogen and CD62-P expression by atRA remain to
be elucidated, further studies should be carried out to
investigate the underlying mechanisms of the inhibition of
ﬁbrinogen and CD62-P expression by atRA, as well as the8 Journal of Biomedicine and Biotechnology
optimal dosage and route of administration, so that its pro-
tective eﬀects can be maximized and side eﬀects be reduced.
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